Medtronic reports full year and fourth quarter fiscal 2024 financial results; announces dividend increase

Broad-based, durable growth across the company, including cranial & spinal technologies, diabetes, cardiac pacing, surgical, and structural heart; gaining momentum as company enters new product cycles across many high-growth markets dublin , may 23, 2024 /prnewswire/ -- medtronic plc (nyse:mdt) today announced financial results for its fourth quarter (q4) and fiscal year 2024 (fy24), which ended april 26, 2024. key highlights q4 revenue of $8.6 billion increased 0.5% as reported and 5.4% organic q4 gaap diluted earnings per share (eps) of $0.49; non-gaap diluted eps of $1.46 fy24 revenue of $32.4 billion increased 3.6% as reported and 5.2% organic fy24 gaap diluted eps of $2.76; non-gaap diluted eps of $5.20 fy24 cash from operations of $6.8 billion increased 12%; fy24 free cash flow of $5.2 billion increased 14% company returned $5.5 billion to shareholders in fy24, including $1.6 billion through net share repurchases in q4 company issues fy25 guidance dividend increased to $0.70 per share quarterly, annual $2.80 per share; 47th consecutive year of dividend increases received u.s. fda approval for evolut™ fx+ tavr system and inceptiv™ closed-loop spinal cord stimulator; received china national medical products administration (nmpa) approval for symplicity spyral™ renal denervation system; submitted affera sphere-9™ ablation catheter and simplera sync™ cgm to u.s. fda seeking approval q4 financial results medtronic reported q4 worldwide revenue of $8.589 billion, an increase of 0.5% as reported and 5.4% on an organic basis.
MDT Ratings Summary
MDT Quant Ranking